TD Cowen Maintains Buy on Exagen, Raises Price Target to $10
TD Cowen analyst Dan Brennan maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $10.
Read original at benzingaStocks · News reference
Exagen Raises FY2026 Sales Guidance from $70.000M-$73.000M to $72.000M-$75.000M vs $71.560M Est
Exagen (NASDAQ:XGN) raises FY2026 sales outlook from $70.000 million-$73.000 million to $72.000 million-$75.000 million vs $71.560 million estimate.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 4, 2026, 12:01 PM
- Checked
- Aug 4, 2026, 12:01 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
B. Riley Securities Reiterates Buy on Exagen, Raises Price Target to $12
B. Riley Securities analyst Anderson Schock reiterates Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $12.
Read original at benzingaBTIG Maintains Buy on Exagen, Raises Price Target to $9
BTIG analyst Mark Massaro maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $9.
Read original at benzingaExagen shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY2026 sales guidance above estimates.
Read original at benzinga